Foghorn Therapeutics(FHTX)
Focus: Foghorn Therapeutics is a public biotech company focused on cancer drug discovery through protein degradation mechanisms. They operate as a clinical-stage oncology specialist with a lean public company structure.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
2-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Foghorn Therapeutics?
AI assessmentHigh-science opportunity with platform-stage optionality, but significant near-term financial pressure and clinical validation risk make this suitable only for risk-tolerant scientists seeking equity upside over stability.
Why Work Here
- Cutting-edge protein degradation platform in high-demand oncology space with potential for multiple clinical successes
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$23M
Pipeline & Clinical Trials
FHD-609
Advanced Synovial SarcomaClinical Trials (1)
NCT04965753FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Phase 1Help build intelligence for Foghorn Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.